

AMD A-to-OCT-to-RI-to-Z

What You Need to Know

Greg A. Caldwell, OD, FAAO
Optometric Education Consultants
August 30, 20/20



Disclosures- Greg Caldwell, OD, FAAO

- ☞ Will mention many products, instruments and companies during our discussion
 - ★ I don't have any financial interest in any of these products, instruments or companies
- ☞ Pennsylvania Optometric Association –President 2010
 - ☐ POA Board of Directors 2006-2011
- ☞ American Optometric Association, Trustee 2013-2016
- ☞ I never used or will use my volunteer positions to further my lecturing career
- ☞ Lectured for: B&L, Shire, BioTissue, Maculogix, Optovue, Alcon, Allergan, Aerie
- ☞ Advisory Board: Alcon, Allergan, Maculogix, Sun
- ☞ Envolve: PA Medical Director, Credential Committee
- ☞ Optometric Education Consultants - Scottsdale, WDW, St. Paul, Quebec City, and Nashville, Owner



Course Description and Objectives

This course will evaluate Age Related-Macular Degeneration (AMD) from subclinical to advanced AMD. It will emphasize structure (OCT) and function (dark adaptation) testing to provide early detection and proper staging of AMD. Once accurately diagnosed the course will discuss applying current clinical guidelines in the treatment of subclinical to advanced AMD. The course will also call attention to OCT structural changes indicating progression.

Course Objectives:

- ☞ Show how to diagnose the often missed subclinical or early AMD
- ☞ Increase ones understanding on function testing for AMD
- ☞ Increase ones understanding on the structure changes to properly stage AMD
- ☞ Show how to treat subclinical or early AMD
- ☞ Discuss OCT Angiography utilization in AMD
- ☞ Review treatments for Intermediate AMD
- ☞ Review treatments for exudative/choroidal neovascular AMD

AMD Dominance

- ✪ In 2010, the World Health Organization estimated that 5% of the world's blindness was due to AMD
- ✪ Leading cause of blindness over 55-year-old in USA
- ✪ 11 million people in USA have AMD, 22 million by 2050
 - ★ Approximately 1 in 14 people over the age of 40 has some degree of macular degeneration
 - ★ Over 60, 1 in 8 (12.5%)
 - ★ Over 80, 1 in 3 (33 %)
- ✪ More cases of AMD than Alzheimer's, breast cancer, and Parkinson's combined
- ✪ The leading cause of blindness and vision loss in Caucasians
- ✪ Affect 1 in 5 families
- ✪ Hereditary strongest genetic linkage of any major diseases

Eye Care Professional Landscape

 58,000 eye care professionals

★ 40,000 optometrists


★ 18,000 ophthalmologists

📄 About 10% are retinal specialists


Age-Related Macular Degeneration is the Leading Cause of Preventable Blindness in the Western World

 Clinical AMD is more prevalent than Glaucoma and Diabetic Retinopathy combined

PREVALENCE OF MAJOR EYE DISEASES (US)



CNV PATIENT OUTCOMES ON 1ST PRESENTATION FOR Anti-VEGF TREATMENT



Primary Eye Care is Missing Visible Disease in 25% of Patients Using Standard Workup

JAMA Ophthalmology | Original Investigation

Prevalence of Undiagnosed Age-Related Macular Degeneration in Primary Eye Care

David C. Neely, MD; Kevin J. Bray, MD; Carrie E. Huisingsh, MPH; Mark E. Clark, BS; Gerald McGwin Jr, PhD; Cynthia Owsley, PhD

1288 eyes from 644 people

- Mean age of 69.4
- 36% male

Doctors were aware that they were recruiting patients for an AMD study!!!

- ✓ 25% of eyes were consistent with AMD
- ✓ 30% of missed AMD eyes had large drusen (Intermediate AMD)
 - ✓ Well-known risk factor for progression to advance disease
- ✓ ODs and MDs miss AMD diagnosis equally

AMD Considerations and Pearls

- 👁️ There is currently no cure for AMD
 - ★ Proper detection and care may prevent significant visual acuity loss in many patients
- 👁️ Are anti-VEGF injections our patients' best hope?
- 👁️ Late-stage treatments, albeit necessary, they have little impact on central acuity
 - ★ Impacting our ability to intervene in early to intermediate AMD?


Optometrists and All Eye Care Professionals Responsibility

- 👁️ Rethink our responsibility related AMD diagnosis and management
- 👁️ Commit to that we will do better in
 - ★ Early detection
 - ★ Treatment
- 👁️ Know, execute, and employ current clinically appropriate Practice Guidelines
 - ★ Those that preserve vision
 - ★ Don't wait until vision has been lost
- 👁️ Closely monitor and treat the early detected disease
 - ★ If progresses to advanced AMD, better opportunity to save vision

ODs on Facebook 44

Chad Feltows
September 18 at 11:43 PM

Loss of foveal pit with macular texture and drusen appearance which may be vitelliform. Anular normal OI, VA OD 20/25 - OS 20/30+. Mild cataracts o.a. Who sends to retina? Who monitors? Optima?



1 Like

Elisa Gonzalez Monitor
Like · 1 day · 24

Tracy Kinnelstein Guest Monitor
Like · 1 day · 23

Elaine E. Sposito Monitor
Like · 1 day · 21

Steve Guntman what's she's going to do with it? monitor
Like · 1 day · 20

Dr. Alan Olsberg Member & 3 mos with home profile
Like · 1 day · 14

Mark Weber Monitor
Like · 1 day · 11

Aashish Rajwani Monitor
Like · 1 day · 11

PEOPLE MENTIONED

DESCRIPTION

This community is PRIVATE. ODs, students, Opticians, Industry/Ops... See More

GROUP TYPE

Social Learning

CREATE NEW GROUPS

Groups make it easier than ever to stay up with friends, family and local tribes. [Create Group](#)

UPCOMING GROUP EVENTS

21st Annual Ocular Therapeutics in Contact Lens Program
March 11, 2022 - March 16, 2022
Cancun, Mexico
Created by ODs on Facebook 44

OE in Italy/Europe Several in the Spring 2020 Heidelberg
April 26, 2020 - April 28, 2020
Heidelberg Germany
James Powell invited you to attend for ODs on Facebook 44

RECENT GROUP POSTS

English (UK) · Spanish (Spain) · Portuguese (Brazil) · Danish

Privacy · Terms · Advertising · Ad Choices · Cookies · More

Facebook © 2019

ODs on Facebook 44

1 day · 24

Tracy Kinnelstein Guest Monitor
Like · 1 day · 23

Elaine E. Sposito Monitor
Like · 1 day · 21

Steve Guntman what's she's going to do with it? monitor
Like · 1 day · 20

Dr. Alan Olsberg Member & 3 mos with home profile
Like · 1 day · 14

Mark Weber Monitor
Like · 1 day · 11


Aashish Rajwani Monitor
Like · 1 day · 11

ODs on Facebook 44

1 day · 24

Chad Feltows
September 18 at 11:43 PM

Loss of foveal pit with macular texture and drusen appearance which may be vitelliform. Anular normal OI, VA OD 20/25 - OS 20/30+. Mild cataracts o.a. Who sends to retina? Who monitors? Optima?



1 day · 24

David Johnson Based out of Ohio. Don't forget monitor! You might prefer another
Like · 1 day · 21

Mark O'Boyley Fellow isn't that what you're all about (24)
Like · 1 day · 14

Steve Guntman (24) aren't you're been told 20/20 or worse, if WE involved, they will not longer. How would you like to do 100% of someone's job to have them see the world or work they going to. Tough call.
Like · 1 day · 14

PEOPLE MENTIONED

DESCRIPTION

This community is PRIVATE. ODs, students, Opticians, Industry/Ops... See More

GROUP TYPE

Social Learning

CREATE NEW GROUPS

Groups make it easier than ever to stay up with friends, family and local tribes. [Create Group](#)

UPCOMING GROUP EVENTS

21st Annual Ocular Therapeutics in Contact Lens Program
March 11, 2022 - March 16, 2022
Cancun, Mexico
Created by ODs on Facebook 44

OE in Italy/Europe Several in the Spring 2020 Heidelberg
April 26, 2020 - April 28, 2020
Heidelberg Germany
James Powell invited you to attend for ODs on Facebook 44

RECENT GROUP POSTS

English (UK) · Spanish (Spain) · Portuguese (Brazil) · Danish

Privacy · Terms · Advertising · Ad Choices · Cookies · More

Facebook © 2019


Early Onset Pathogenesis

- ↳ Drusen small or large are not makers for early stage AMD
 - ★ Visible structural evidence of a pathological process
 - ↳ Underway for quite some time
- ↳ Cholesterol deposits exist beneath the surface long before drusen form
 - ★ Cannot be seen with structure-based methods
 - ★ Cholesterol produced by RPE and deposits into Bruch's membrane
 - ★ Continue to layer in Bruch's membrane
- ↳ As this cholesterol accumulates the process unfolds with compromise to the outer retina
 - ★ Inflammation
 - ★ Oxidative stress
 - ★ Disruption of oxygen and nutrients
 - ★ Drusen formation
- ↳ Impaired Vitamin A across Bruch's membrane
 - ★ Functional impairment can occur to dark adaptation


Healthy choriocapillaris, Bruch's, RPE, and Photoreceptors





Cholesterol barrier deposited along Bruch's and RPE




RPE Secretes even more cholesterol and degenerates



Finally, visibly evident drusen on fundus evaluation



AMD is a Disease Process that Starts Below the Surface



Staging of Drusen

What method to detect?

↳ Sub-clinical or sub-structural – cholesterol layer	Functional
↳ Small drusen < 63 microns	Exam, photos, SD-OCT
↳ Medium drusen > 63 – <125 microns	Exam, photos, SD-OCT
↳ Large drusen > 125 microns	Exam, photos, SD-OCT

Beckmann Committee Classification of AMD

Based on presence of lesions within 2 DD of fovea in either eye

- ★ No AMD

- ☐ None or few small drusen, < 63 microns
- ☐ No AMD pigmentary abnormalities

- ★ Early AMD

- ☐ Medium drusen, > 63 – <125 microns
- ☐ No AMD pigmentary changes



- ★ Intermediate AMD

- ☐ 1 large drusen, > 125 microns
- ☐ Any AMD pigmentary changes



- ★ Advanced AMD

- ☐ Any geographic atrophy
- ☐ Choroidal neovascularization (CNV)


Measure the Drusen with Your OCT



Measure the Drusen with Your OCT



Measure the Drusen with Your OCT



Choroidal Neovascularization (CNV)

- 👁️ Type 1 – Occult
- 👁️ Type 2- Classic
- 👁️ Type 3- RAP
- 👁️ Type 4- Mixed

Predictors of Progressing to Advance Disease

- 👁️ Hyper-reflective foci
- 👁️ Reticular pseudodrusen
- 👁️ Nascent geographic atrophy
- 👁️ Sub-RPE hyper-reflective columns
- 👁️ Drusen substructures
- 👁️ Drusen load and regression
- 👁️ Vision loss from geographic or exudative/CNV

Tools for Diagnosis, Management, and Treatment of AMD

- 👁️ Comprehensive eye exam – structural, some functional
- 👁️ Fundus photography and FAF - structural
- 👁️ OCT and OCT Angiography – structural
- 👁️ Dark adaptation – functional

- 👁️ How about macula pigment density testing

Applying a Familiar Standard of Care: *Two Multifactorial Diseases*

Glaucoma

AMD

Structure



Cup-to-disc
Ratio



Drusen

Function



Visual Field



Dark Adaptation

Risk

Intraocular Pressure (IOP)
Corneal Thickness
Age/race
Family history/etc.
Health and Lifestyle (Diabetes)



Age
Genetic Testing
Health and Lifestyle (Smoking)
Macular Pigment Optical Density (MPOD)
Contrast Sensitivity.

Dark Adaptation in AMD

Function Test

- 👁️ Measures how long to recover from bright light to darkness
 - ★ Rod intercept line (RI) time
- 👁️ Functional test that can help overcome the challenges in diagnosing AMD
- 👁️ Alabama Study on Early Age-Related Degeneration (ALSTAR)
 - ★ Able to detect subclinical 3 years before clinically visible
 - ★ 325 adults without clinically detectable AMD
- 👁️ Rod deterioration happens in earliest stages of AMD
 - ★ Earlier detection before visual acuity
- 👁️ AdaptDx 92284
 - ★ Sensitivity 90.6%
 - ★ Specificity 90.5%





Dark Adaptation in AMD


Function Test

January 1st, 2020


AdaptDx Pro Now Available for Clinical Use



This Means We Now Have an *Early Symptom* We Can Use to Help Diagnose AMD



- Night vision impacted in early AMD: 30+ studies
- AMD patients often give up driving at night
- Night vision is impaired before day vision
- Typically ECP's chalk this complaint up to cataracts




***Ask Every Patient Over 50
About Their Night Vision***

OCT in AMD

- 👉 Need spectral domain to follow intermediate or worse AMD
- 👉 Able to identify OCT predictors of progression
- 👉 Especially in identifying OCT predictors of progression
 - ★ Hyper-reflective foci
 - ★ Reticular pseudodrusen
 - ★ Nascent geographic atrophy
 - ★ Sub-RPE hyper-reflective columns
 - ★ Drusen substructures
 - ★ Drusen load and regression

Hypo versus Hyper Reflectance




Can We Learn From These Pictures?




Can We Learn From These Pictures?




Hypo versus Hyper Reflectance




Case 1 - OCT Predictors of Progression




Case 1 - OCT Predictors of Progression




Case 1 - OCT Predictors of Progression




Case 2 - OCT Predictors of Progression




Case 2 - OCT Predictors of Progression




Case 2 - OCT Predictors of Progression




Case 3 - OCT Predictors of Progression




Case 4 - OCT Predictors of Progression




Case 5 - OCT Predictors of Progression



Case 5 - OCT Predictors of Progression



Case 5 - OCT Predictors of Progression



OCT Angiography in AMD

Structure Test


- ↳ Able to identify occult or classic CNV before they leak
- ↳ Non-invasive technique
- ↳ Subclinical CNV or “Occult non-exudative CNV”
 - ★ Risk of exudation at 12 months is 15.2 times greater compared to eyes without subclinical CNV

OCT Angiography A New Approach to Protecting Vision

- ▶ Non-invasive visualization of individual layers of retinal vasculature
- ▶ Pathology not obscured by fluorescein staining or pooling
- ▶ Image acquisition requires less time than a dye-based procedure
- ▶ Reduced patient burden allows more frequent imaging to better follow disease progression and treatment response




FA of CNV




OCTA of CNV

Enface OCT-A Slabs Based on Retinal Anatomy



Normal Retinal Vasculature



Superficial Capillary Plexus

3 μ m Below ILM \rightarrow 15 μ m
Below IPL

Deep Capillary Plexus

15 μ m Below ILM \rightarrow 70 μ m
Below IPL


Outer Retina

70 μ m Below IPL \rightarrow 30 μ m
Below RPE Reference

Choriocapillaris

30 μ m Below RPE Reference \rightarrow 60 μ m
Below RPE Reference



Type 1 “Occult” CNV



- ▶ New vessels develop in the choroid
- ▶ New vessels located below RPE and above Bruch's membrane

Type 1 “Occult” CNV


- ↳ New vessels develop in the choroid
- ↳ New vessels located **BELOW RPE** and **ABOVE** Bruch’s membrane




RPE

Bruch's
Membrane


Choroid




CNV?







72 y/o Hispanic male
20/30
History of "Dry AMD"



Multimodal imaging and OCTA







VAGUE???





Vascularized



Non-vascularized

Type 1 CNV: Below RPE, Wider than Type 2, Avascular Zone Usually Not Involved




And the not so obvious ones...








6x6


3x3



Case example: 70 y/o WM, AMD






Type 2 “Classic” CNV




- ☞ New vessels develop in choroid
- ☞ New vessels located above the RPE and above Bruch's membrane

Type 2 “Classic” CNV


- ↪ New vessels develop in choroid
- ↪ New vessels located **ABOVE** the RPE and **ABOVE** Bruch’s membrane




**Type 2 CNV: Above RPE, Smaller than Type 1, Avascular Zone Always Involved.
Very Heterogeneous Shapes**



48 y/o WM 2 week history of “dark spot” OD



Retinal Angiomatous Proliferation



Stage 1

Intra-retinal proliferation

- *Hemes
- *Edema
- *Exudate

Stage 2


Neovascularization penetrates the sub-retinal space

- *Neurosensory detachment
- *Serous PED

Stage 3

Neovascularization penetrates the RPE space


- *Vascularized PED; CNVM



https://www.researchgate.net/figure/In-retinal-angiomatous-proliferation-fluorescein-angiography-FA-shows-a-hot-spot-in_fig8_264903506

<https://jamanetwork.com/journals/jamaophthalmology/fullarticle/42089>

Inspect the SD-OCT carefully!!




VA 20/40


HYPER-REFLECTIVE lesion above pigment epithelial detachment

Intraretinal cysts



Serous pigment epithelial detachment/ neurosensory detachment

Stage 2





Stage 3




<http://imagebank.asrs.org/file/26943/retinal-angiomatous-proliferation>
<https://www.ncbi.nlm.nih.gov/pubmed/29019795>

What about the OCTA?

OCT angiography demonstrates retinal angiomatous proliferation and chorioretinal anastomosis of type 3 neovascularization

Swati Bansal · Virendra Bansal · Sameek Mukherjee · Rameshwar Singh ·
Yishai Gupta · Manoj K. Datta · Anand Gupta

Type 3 CNV: Intraretinal Anastomosis: THROUGH RPE




Inner retina (SCP+DCP) to Outer retina (Avascular/choriocapillaris)

What about the OCTA?

OCT angiography demonstrates retinal angiomatous proliferation and choriorretinal anastomosis of type 3 neovascularization

Roopa Bansal - Scribble Demuth - Sanyal Mukherjee - Ramakrishna Shetty -
Yishai Gupta - Manoj K. Deyra - Anand Gupta.


Type 3 CNV: Retinal/Choroidal Anastomosis: INTO CHOROID




Inner retina (SCP+DCP) to Outer retina (Avascular/choriocapillaris)

Type 4 “Mixed” - Subretinal and Sub-RPE

- Two or more CNV layers
 - ★ One above the RPE, one below the RPE
- High flow lesions




Type 4 CNV : Initially Located Below the RPE, NV Spreads into the Outer Retina




Angio - Deep



Angio - Outer Retina




Angio - Choroid Capillary



Green: Type 1 (Sub RPE)
Yellow: Type 2 (Subretinal)

Case Example: Multimodal imaging of 66 y/o Caucasian male



Fundus image
and Occult




FFA: Early; Classic component



FFA: Late; Classic

Courtesy of Novais et al.



Choriocapillaris

Red: Occult; Yellow: Classic


Courtesy of Novais et al.

OCT Angiography


Subclinical CNV or “Occult non-exudative CNV”

Risk of exudation at 12 months is 15.2 times greater compared to eyes without subclinical CNV


Occult
Non-Exudative
CNV
Patient A



Occult
Non-Exudative
CNV
Patient A



Occult
Non-Exudative
CNV
Patient A



Which is More Suspicious?

HD Angio Retina

Scan Quality 7/10

Right / OD

6.00 x 5.00 Scan Size (mm)

3D Display

OverVue

QuickVue

Edit Bnd

Restore Settings

Play

Export Angio

SLD En Face Thickness RPE Elevation Color Overlay


Measure OCT

1.07

1.06



The image displays a side-by-side comparison of two OCT scans. The top row shows the 'En Face' view for two different scans, with a red vertical line indicating the location of the cross-sections below. The bottom row shows the corresponding cross-sectional views. The left cross-section shows a significant area of red, indicating fluid accumulation or leakage. The right cross-section shows a more normal retinal structure. The interface includes various controls like 'Measure OCT', 'Export Angio', and '3D Display'.

OCT Angiography Evaluation AMD




OCT Angiography Evaluation AMD

After and Before Bevacizumab (Avastin)





Evaluation AMD Patients for Neovascularization

OCT Grid



Evaluation AMD Patients for Neovascularization

Using OCT Angiography



Treatments for AMD

🔗 Early detection and meaningful treatments with significant value, do not cure, but have been shown to slow or halt progression. Not limited to early stages but all stages of AMD

- ★ Prescribe smoking cessation programs

- 📄 Smoking and AMD

- Depletes serum antioxidants
 - Decreases pigmentary density
 - Increases risk to advanced AMD

- ★ Lifestyle changes

- 📄 Diet

- 📄 Exercise

- ★ Systemic disease management

- 📄 Cardiovascular disease, DM, obesity, high cholesterol

Treatment for AMD

🔗 Nutritional supplements

★ Sub-clinical/sub-structural or early disease

- 📄 Controversy flourishes
 - No definitive guideline exists
 - Despite consensus evidence suggests using supplements

★ Intermediate – advance disease

- 📄 No controversy on advocating for supplements

★ AREDS 1

- 📄 Contains Beta-carotene and no lutein or zeaxanthin, no longer recommended
- 📄 Investigated early AMD, no statistically significant benefit

★ AREDS 2

- 📄 Recommended for intermediate and advanced AMD, study protocol

★ The Practical Guide for the Treatment of AMD - 3 primary options

- 📄 Macular pigment supplement
 - Carotenoids: lutein, zeaxanthin, meso-zeaxanthin
- 📄 Carotenoids, antioxidants, zinc, and vitamins C & E
 - AREDS 2
- 📄 Carotenoid macular supplement in subclinical and early AMD. Carotenoid and antioxidant is intermediate and AMD that is progressing

Treatment for AMD

Retinal light protection

- ★ Sun exposure

Closer follow up

- ★ 12 months is currently accepted as being too long to detect progression
- ★ 6 months or sooner based on risk of CNV

Low vision and rehabilitation consultation

Treatments for Choroidal Neovascularization (CNV)

🔗 Current Anti-VEGF treatments

- ★ Bevacizumab (Avastin)
 - 📄 Humanized full length monoclonal antibody
 - 📄 AMD
- ★ Ranibizumab (Lucentis)
 - 📄 Humanized monoclonal antibody fragment
 - 📄 AMD, DME, DR, RVO
- ★ Aflibercept (Eylea)
 - 📄 Fusion protein
 - 📄 AMD, DME, DR
- ★ brolucizumab-dbll (Beovu)
 - 📄 Humanized single-chain antibody fragment
 - 📄 Up to 3 months dosing intervals, most are 4-6 weeks
 - 50% remained 3 months after 1 year
- ★ Pegaptanib (Macugen)
 - 📄 RNA aptamer
 - 📄 AMD


ODs on Facebook

- Private group
- About
- Discussion
- Announcements
- Members
- Events
- Videos
- Photos
- Files
- Recommendations
- Watch Party

Search this group

- Shortcuts
- ODT Contact
- Optometric Research
- ODs on Facebook
- Opt. Center, Info, ELEM
- Medical Optometry Am.
- Opt. 2022
- Optometric Nation
- Optometric of Am.
- POA ODs on Facebook
- Optometric Optics
- Starfield Family Events
- Walt Disney World A.S.
- Managed Medicaid in R.
- Eyewr OD's
- Davis Vision Center

Chad Feltows
 Commented 1h at 1:03 PM
 Lots of good info with these. I think you may be right. Amalar. I think you're right. Who sends to



- Like
- Ellen Overholt M.D. Like · Reply · 2d
- Tracy Kinnaman D. Like · Reply · 2d
- Elaine R. Spawthorpe M.D. Like · Reply · 2d
- Shane Blumhans who Like · Reply · 2d
- Dr. Alan Glazier M.D. Like · Reply · 2d
- Mick Weber M.D. Like · Reply · 2d
- Acacia Raymond M.D. Like · Reply · 2d

ODs or

- Private
- About
- Discuss
- Announc
- Member
- Events
- Videos
- Photos
- Files
- Recomm
- Watch P
- Search t
- Shortcuts
- OCT
- Optor
- ODs
- Dr. C
- Medic
- CME4
- Steele
- Optor
- POA
- Corpe
- Sawft
- Walt
- Mans
- Eyeris
- Davis

then going in. Tough call.

Like · Reply · 1d



Greg Caldwell Chad, great case to present. Regarding the ERM I agree with my colleagues about monitor. I agree this does not need to see retina based on the ERM and drusen. I am going to respectfully disagree about just monitoring these drusen and this patient. I will start off by saying there are only 4 OCTs to review, looking at more would help support my thoughts, but the two here are enough for me to weigh in. The OCTs on the left side top and bottom are showing signs of progression and that the RPE is sicker than just monitor. At the top of these drusen are hyper-reflective foci a sign of progression. In the top left OCT I see two columns of sub-RPE hyper-reflective columns and the bottom left 5-6 columns. The RPE absorbs the OCT (coherent) light typically keeping the choroid black. These hyper-reflective columns are like rays of sunlight poking through on a cloudy day. The RPE is atrophied here and the OCT coherent light is making its way into the choroid. This RPE is sicker than you think, it's oxidized, inflamed, it's sick. Rather than monitor based upon hyper-reflective foci and sub-RPE hyper-reflective columns I would treat this patient. Treatment would be to stop smoking if the patient is a smoker, discuss his/her diet and exercise, discuss the best possible management for his/her (systemic health) DM, cholesterol, obesity, cardiovascular, as these are all risk factors in AMD. Sunglasses in any ultraviolet light. Prescribe nutritional supplements, this RPE is sick enough to recommend AREDS2, if you want to avoid the high zinc levels then do something with 25 mg of zinc, or at least triple carotenoid therapy (lutein, zeaxanthin, and meso-zeaxanthin). These OCTs with the drusen size, foci, and columns are signs the patient is moving toward advanced AMD which is geographic atrophy and/or CNV. Julie Friedman Rodman any other comments? Alan Glazier this would be a great case to present when we share the podium again on cases from ODs on FB. Respectfully, Greg

Like · Reply · 2m



Writes a comment...



Message

Go to Units

Share to share



9,870 Members



1 students, 10

Create Group

See All

17 Lancun CE

March 15,

5

1 Bavaria

April 26,

5 try ad you to in

See All



Click on a page for group activities to share knowledge and resources with you.

Join a community

1. 100 members

2. 100 members

3. 100 members

4. 100 members

5. 100 members

6. 100 members

7. 100 members

8. 100 members

9. 100 members

10. 100 members

11. 100 members

12. 100 members

13. 100 members

14. 100 members

15. 100 members

16. 100 members

17. 100 members

18. 100 members

19. 100 members

20. 100 members

21. 100 members

22. 100 members

23. 100 members

24. 100 members

25. 100 members

26. 100 members

27. 100 members

28. 100 members

29. 100 members

30. 100 members

31. 100 members

32. 100 members

33. 100 members

34. 100 members

35. 100 members

36. 100 members

37. 100 members

38. 100 members

39. 100 members

40. 100 members

41. 100 members

42. 100 members

43. 100 members

44. 100 members

45. 100 members

46. 100 members

47. 100 members

48. 100 members

49. 100 members

50. 100 members

51. 100 members

52. 100 members

53. 100 members

54. 100 members

55. 100 members

56. 100 members

57. 100 members

58. 100 members

59. 100 members

60. 100 members

61. 100 members

62. 100 members

63. 100 members

64. 100 members

65. 100 members

66. 100 members

67. 100 members

68. 100 members

69. 100 members

70. 100 members

71. 100 members

72. 100 members

73. 100 members

74. 100 members

75. 100 members

76. 100 members

77. 100 members

78. 100 members

79. 100 members

80. 100 members

81. 100 members

82. 100 members

83. 100 members

84. 100 members

85. 100 members

86. 100 members

87. 100 members

88. 100 members

89. 100 members

90. 100 members

91. 100 members

92. 100 members

93. 100 members

94. 100 members

95. 100 members

96. 100 members

97. 100 members

98. 100 members

99. 100 members

100. 100 members

Resource: OCT Community for OCT and OCT-A




OCT CONNECT


Post your questions & cases so we can #OCTConnect!



Join this group to become part of our
OCT Connect Family!




Book Resources



Optical Coherence Tomography Angiography Atlas: A Case Study Approach

Julie A Rodman, OD MSc FAAO



\$149.95

ISBN 10 1-63001-641-2

ISBN 13 978-1-63001-641-1

200 pp Hard Cover

Pub. Date: 2019

Order# 66411

Thank-You and Hope You Enjoyed

Greg Caldwell, OD, FAAO
Grubod@gmail.com

